Dapiglutide (GLP-1/GLP-2 Dual Agonist)
Dapiglutide is a long-acting, dual GLP-1R/GLP-2R agonist for the potential treatment of obesity. This is a first-in-class peptide designed to leverage the weight loss effects of a potent GLP-1 agonist and address co-morbidities associated with low-grade inflammation through improved intestinal barrier function by GLP-2.
A Phase 2 investigator-led randomized, double-blind, placebo-controlled clinical trial in up to 54 people living with overweight and obesity, named DREAM, aims to evaluate the potential for weight loss and gain key mechanistic insights into the effects of dapiglutide on inflammatory markers following a 12-week treatment period.
Separately, Zealand has initiated a 13-week randomized, double-blind, placebo-controlled, dose titration trial to evaluate higher doses of dapiglutide in overweight or obese but otherwise healthy people (eligible BMI 27.0–39.9).